{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T19:24:35Z","timestamp":1794684275837,"version":"4.9.1"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":25,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014382","name":"Ipsen Pharma SAS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013733","name":"Ipsen Biopharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013733","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jhep.2026.08.016","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T06:51:39Z","timestamp":1787813499000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Elafibranor in primary biliary cholangitis: Two-year placebo-controlled outcomes and long-term open-label data from the ELATIVE\u00ae phase III trial"],"prefix":"10.1016","author":[{"given":"Kris V.","family":"Kowdley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3906-6811","authenticated-orcid":false,"given":"Christopher L.","family":"Bowlus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5498-6037","authenticated-orcid":false,"given":"Cynthia","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7020-5816","authenticated-orcid":false,"given":"Ulus","family":"Akarca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5001-246X","authenticated-orcid":false,"given":"Mario Reis","family":"Alvares-da-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4794-9809","authenticated-orcid":false,"given":"Pietro","family":"Andreone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Arrese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7920-9784","authenticated-orcid":false,"given":"Christophe","family":"Corpechot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6925-264X","authenticated-orcid":false,"given":"Hany","family":"Elbeshbeshy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Francque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Heneghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3262-1998","authenticated-orcid":false,"given":"Pietro","family":"Invernizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira M.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9263-948X","authenticated-orcid":false,"given":"Andreas E.","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik C.","family":"Kruger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Kugelmas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4234-224X","authenticated-orcid":false,"given":"Eric","family":"Lawitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4874-7010","authenticated-orcid":false,"given":"Marlyn J.","family":"Mayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3575-6516","authenticated-orcid":false,"given":"Mitchell L.","family":"Shiffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7128-8329","authenticated-orcid":false,"given":"Mark","family":"Sonderup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0919-4468","authenticated-orcid":false,"given":"Mark G.","family":"Swain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Miguel","family":"Valera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Vierling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0928-0427","authenticated-orcid":false,"given":"Ares","family":"Villagrasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7152-0976","authenticated-orcid":false,"given":"Alejandra","family":"Villamil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuno","family":"Antunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Raskino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan","family":"Sleiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Cranham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4224-4703","authenticated-orcid":false,"given":"J\u00f6rn M.","family":"Schattenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2026.08.016_bib1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.08.016_bib2","first-page":"121","article-title":"Primary biliary cholangitis: a summary of pathogenesis and therapies","volume":"38","author":"Jallouli","year":"2025","journal-title":"Ann Gastroenterol"},{"key":"10.1016\/j.jhep.2026.08.016_bib3","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American association for the Study of Liver Diseases","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.08.016_bib4","article-title":"Understanding fatigue and pruritus in primary biliary cholangitis","volume":"23","author":"Faisal","year":"2024","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"10.1016\/j.jhep.2026.08.016_bib5","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/hep.26365","article-title":"Impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC national study","volume":"58","author":"Mells","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.08.016_bib6","doi-asserted-by":"crossref","first-page":"771","DOI":"10.5009\/gnl16365","article-title":"Extrahepatic manifestations of primary biliary cholangitis","volume":"11","author":"Chalifoux","year":"2017","journal-title":"Gut Liver"},{"key":"10.1016\/j.jhep.2026.08.016_bib7","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.4254\/wjh.v14.i6.1111","article-title":"Understanding fatigue in primary biliary cholangitis: from pathophysiology to treatment perspectives","volume":"14","author":"Lynch","year":"2022","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jhep.2026.08.016_bib8","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s10620-022-07581-x","article-title":"Impact of pruritus on quality of life and current treatment patterns in patients with primary biliary cholangitis","volume":"68","author":"Mayo","year":"2023","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2026.08.016_bib9","first-page":"5","article-title":"An examination of the evidence behind biochemical markers in primary biliary cholangitis","volume":"17","author":"Kowdley","year":"2021","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"10.1016\/j.jhep.2026.08.016_bib10","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","article-title":"Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study","volume":"147","author":"Lammers","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2026.08.016_bib11","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.cgh.2020.08.006","article-title":"Measurement of gamma glutamyl transferase to determine risk of liver transplantation or death in patients with primary biliary cholangitis","volume":"19","author":"Gerussi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.08.016_bib12","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.14309\/ajg.0000000000000557","article-title":"Goals of treatment for improved survival in primary biliary cholangitis: treatment target should be bilirubin within the normal range and normalization of alkaline phosphatase","volume":"115","author":"Murillo Perez","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2026.08.016_bib13","doi-asserted-by":"crossref","first-page":"E178","DOI":"10.1111\/hepr.12746","article-title":"Liver fibrosis progression predicts survival in patients with primary biliary cirrhosis","volume":"47","author":"Namisaki","year":"2017","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2026.08.016_bib14","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/MCG.0000000000001433","article-title":"Liver stiffness measured by either magnetic resonance or transient elastography is associated with liver fibrosis and is an independent predictor of outcomes among patients with primary biliary cholangitis","volume":"55","author":"Osman","year":"2021","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2026.08.016_bib15","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","article-title":"Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis","volume":"48","author":"Corpechot","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.08.016_bib16","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.dld.2017.05.001","article-title":"Primary biliary cholangitis: advances in management and treatment of the disease","volume":"49","author":"Invernizzi","year":"2017","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhep.2026.08.016_bib17","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2026.08.016_bib18","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.14309\/ajg.0000000000002238","article-title":"Effectiveness of fenofibrate in treatment-naive patients with primary biliary cholangitis: a randomized clinical trial","volume":"118","author":"Liu","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2026.08.016_bib19","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jhep.2021.04.010","article-title":"Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis","volume":"75","author":"Tanaka","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.08.016_bib20","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","article-title":"Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid","volume":"148","author":"Hirschfield","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2026.08.016_bib21","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.cgh.2023.02.005","article-title":"New treatment paradigms in primary biliary cholangitis","volume":"21","author":"Levy","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.08.016_bib22","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jhep.2024.04.008","article-title":"Assessment of fatigue and its impact in chronic liver disease","volume":"81","author":"Younossi","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.08.016_bib23","series-title":"LYNAVOY highlights of prescribing information","year":"2026"},{"key":"10.1016\/j.jhep.2026.08.016_bib24","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.cld.2022.06.009","article-title":"Evaluation and management of pruritus in primary biliary cholangitis","volume":"26","author":"D\u00fcll","year":"2022","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jhep.2026.08.016_bib25","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1007\/s10620-023-07862-z","article-title":"Cholestatic pruritus treatments in primary biliary cholangitis and primary sclerosing cholangitis: a systematic literature review","volume":"68","author":"Smith","year":"2023","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2026.08.016_bib26","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1111\/apt.70634","article-title":"Meta-analysis: PPAR agonists for pruritus and quality of life in primary biliary cholangitis","volume":"63","author":"Martins","year":"2026","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2026.08.016_bib27","series-title":"IQIRVO summary of product characteristics","year":"2024"},{"key":"10.1016\/j.jhep.2026.08.016_bib28","series-title":"IQIRVO highlights of prescribing information","year":"2024"},{"key":"10.1016\/j.jhep.2026.08.016_bib29","series-title":"IQIRVO product monograph","year":"2025"},{"key":"10.1016\/j.jhep.2026.08.016_bib30","series-title":"Australian public assessment report for IQIRVO","year":"2025"},{"key":"10.1016\/j.jhep.2026.08.016_bib31","series-title":"LIVDELZI highlights of prescribing information","year":"2024"},{"key":"10.1016\/j.jhep.2026.08.016_bib32","series-title":"LIVDELZI summary of product characteristics","year":"2024"},{"key":"10.1016\/j.jhep.2026.08.016_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2023.100188","article-title":"PPAR agonists for the treatment of primary biliary cholangitis: old and new tales","volume":"6","author":"Colapietro","year":"2023","journal-title":"J Transl Autoimmun"},{"key":"10.1016\/j.jhep.2026.08.016_bib34","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.3390\/cells13151296","article-title":"PPAR-mediated bile acid glucuronidation: therapeutic targets for the treatment of cholestatic liver diseases","volume":"13","author":"Gallucci","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.jhep.2026.08.016_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910545","article-title":"The role of PPAR alpha in the modulation of innate immunity","volume":"22","author":"Grabacka","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jhep.2026.08.016_bib36","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","article-title":"Molecular mechanism of PPAR\u03b1 action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease","volume":"62","author":"Pawlak","year":"2015","journal-title":"J Hep"},{"key":"10.1016\/j.jhep.2026.08.016_bib37","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/hep.26461","article-title":"Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha\/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"58","author":"Staels","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.08.016_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.102056","article-title":"Selective PPAR\u03b4 agonist seladelpar suppresses bile acid synthesis by reducing hepatocyte CYP7A1 via the fibroblast growth factor 21 signaling pathway","volume":"298","author":"Kouno","year":"2022","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2026.08.016_bib39","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2306185","article-title":"Efficacy and safety of elafibranor in primary biliary cholangitis","volume":"390","author":"Kowdley","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2026.08.016_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2024.102321","article-title":"Extrahepatic conditions of primary biliary cholangitis: a systematic review and meta-analysis of prevalence and risk","volume":"48","author":"Liang","year":"2024","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.jhep.2026.08.016_bib41","article-title":"User manual and scoring instructions","year":"2023","journal-title":"Promis Fatigue"},{"key":"10.1016\/j.jhep.2026.08.016_bib42","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/hep.21609","article-title":"Population prevalence and symptom associations of autonomic dysfunction in primary biliary cirrhosis","volume":"45","author":"Newton","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.08.016_bib43","article-title":"Pruritus significantly impairs quality of life in patients with primary biliary cholangitis","volume":"76","author":"Medina-Morales","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.08.016_bib44","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/j.cgh.2022.10.032","article-title":"GLIMMER: a randomized phase 2b dose-ranging trial of linerixibat in primary biliary cholangitis patients with pruritus","volume":"21","author":"Levy","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.08.016_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0301354","article-title":"High-dose oral thiamine vs. placebo for chronic fatigue in patients with primary biliary cholangitis: a crossover randomized clinical trial","volume":"19","author":"Bager","year":"2024","journal-title":"PLOS One"},{"key":"10.1016\/j.jhep.2026.08.016_bib46","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jclinepi.2010.11.018","article-title":"Minimally important differences were estimated for six Patient-Reported Outcomes Measurement Information System-Cancer scales in advanced-stage cancer patients","volume":"64","author":"Yost","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jhep.2026.08.016_bib70","first-page":"238","article-title":"A simple method for estimating confidence intervals for exposure adjusted incidence rate and its applications to clinical trials","volume":"6","author":"He","year":"2015","journal-title":"J Biom Biostat"},{"key":"10.1016\/j.jhep.2026.08.016_bib47","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1007\/s10620-016-4250-y","article-title":"Long-term fenofibrate treatment in primary biliary cholangitis improves biochemistry but not the UK-PBC risk score","volume":"61","author":"Hegade","year":"2016","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2026.08.016_bib48","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.14309\/ajg.0000000000003603","article-title":"Long-term efficacy and safety of selective PPAR\u03b4 agonist seladelpar in primary biliary cholangitis: ASSURE interim study results","volume":"121","author":"Levy","year":"2026","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2026.08.016_bib49","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/apt.17755","article-title":"Open-label, clinical trial extension: two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis","volume":"59","author":"Mayo","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2026.08.016_bib50","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1111\/apt.16618","article-title":"Bezafibrate therapy in primary biliary cholangitis refractory to ursodeoxycholic acid: a longitudinal study of paired liver biopsies at 5 years of follow up","volume":"54","author":"Sorda","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2026.08.016_bib51","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S2468-1253(19)30094-9","article-title":"Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study","volume":"4","author":"Trauner","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.08.016_bib52","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2312100","article-title":"A phase 3 trial of seladelpar in primary biliary cholangitis","volume":"390","author":"Hirschfield","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2026.08.016_bib53","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2026.08.016_bib54","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s12072-023-10587-w","article-title":"Prognostic significance of liver stiffness in patients with primary biliary cholangitis: validation of Baveno VII criteria","volume":"18","author":"Ding","year":"2024","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2026.08.016_bib55","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000027403","article-title":"Enhanced liver fibrosis score as a surrogate of liver-related complications and mortality in primary biliary cholangitis","volume":"100","author":"Fujinaga","year":"2021","journal-title":"Med (Baltimore)"},{"key":"10.1016\/j.jhep.2026.08.016_bib56","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1111\/liv.15595","article-title":"Validation of scores of PRO-C3 to predict liver-related events in alcohol-related liver disease","volume":"43","author":"Johansen","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2026.08.016_bib57","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/apt.16513","article-title":"PRO-C3 and ADAPT algorithm accurately identify patients with advanced fibrosis due to alcohol-related liver disease","volume":"54","author":"Madsen","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2026.08.016_bib58","article-title":"Systematic review with meta-analysis: diagnostic accuracy of Pro-C3 for hepatic fibrosis in patients with non-alcoholic fatty liver disease","volume":"1920","author":"Mak","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.jhep.2026.08.016_bib59","article-title":"PRO-C3 is a predictor of clinical outcomes in distinct cohorts of patients with advanced liver disease","volume":"5","author":"Nielsen","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2026.08.016_bib60","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000467","article-title":"Serologic extracellular matrix remodeling markers are related to fibrosis stage and prognosis in a phase 2b trial of simtuzumab in patients with primary sclerosing cholangitis","volume":"8","author":"Thorburn","year":"2024","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2026.08.016_bib61","doi-asserted-by":"crossref","first-page":"940","DOI":"10.3390\/diagnostics10110940","article-title":"Diagnostic accuracy of FibroScan and factors affecting measurements","volume":"10","author":"Oeda","year":"2020","journal-title":"Diagnostics"},{"key":"10.1016\/j.jhep.2026.08.016_bib62","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1136\/bmjspcare-2019-002163","article-title":"Placebo response in trials of drug treatments for cancer-related fatigue: a systematic review, meta-analysis and meta-regression","volume":"10","author":"Roji","year":"2020","journal-title":"BMJ Support Palliat Care"},{"key":"10.1016\/j.jhep.2026.08.016_bib63","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1038\/jid.2014.522","article-title":"Placebo effects on itch: a meta-analysis of clinical trials of patients with dermatological conditions","volume":"135","author":"van Laarhoven","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jhep.2026.08.016_bib64","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jhep.2025.04.025","article-title":"Safety and efficacy of elafibranor in primary sclerosing cholangitis: the ELMWOOD phase II randomized-controlled trial","volume":"84","author":"Levy","year":"2026","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.08.016_bib66","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11901-019-00455-3","article-title":"The Role of fibrates in primary biliary cholangitis","volume":"18","author":"Corpechot","year":"2019","journal-title":"Curr Hepatol Rep"},{"key":"10.1016\/j.jhep.2026.08.016_bib67","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S2468-1253(17)30246-7","article-title":"Seladelpar (MBX-8025), a selective PPAR-\u03b4 agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study","volume":"2","author":"Jones","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.08.016_bib68","doi-asserted-by":"crossref","first-page":"779","DOI":"10.2215\/CJN.0000000683","article-title":"The association of fibrate use with kidney outcomes and mortality","volume":"20","author":"Takahashi","year":"2025","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jhep.2026.08.016_bib69","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/j.gastro.2020.10.001","article-title":"Fibrates for itch (FITCH) in fibrosing cholangiopathies: a double-blind, randomized, placebo-controlled trial","volume":"160","author":"de Vries","year":"2021","journal-title":"Gastroenterology"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882782602859X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882782602859X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:14:53Z","timestamp":1791260093000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016882782602859X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":69,"alternative-id":["S016882782602859X"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2026.08.016","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elafibranor in primary biliary cholangitis: Two-year placebo-controlled outcomes and long-term open-label data from the ELATIVE\u00ae phase III trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2026.08.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}